Alcon jumped 9% in Zurich on the day after the ophthalmology laboratory reported core EPS up 11% to $0.78 (+21% at constant exchange rates) for the first three months of 2024.

The Swiss group improved its underlying operating margin by 1.4 points to 22% on sales of $2.44 billion, up 5% (+7% at constant exchange rates), on 'robust sales in contact lenses and eye health'.

On this basis, Alcon is maintaining its main targets for 2024, namely core EPS of three to 3.10 dollars, an underlying operating margin of 20.5 to 21.5%, and sales of 9.9 to 10.1 billion dollars.

Copyright (c) 2024 CercleFinance.com. All rights reserved.